Knyihár-Csillik E, Szücs A, Csillik B
Acta Neurol Scand. 1982 Oct;66(4):401-12. doi: 10.1111/j.1600-0404.1982.tb06863.x.
Transcutaneous iontophoresis of microtubule inhibitors (Vinblastin, Vincristin, Formyl-Leurosin) in rats induces depletion of fluoride-resistant acid phosphatase (FRAP) and transganglionic degenerative atrophy (trggl. deg. atr.) of the central terminals of primary nociceptive neurons, probably via blockade of axoplasmic transport in the peripheral sensory nerves. Radiochemical experiments prove that about 0.2% of the microtubule inhibitors applied iontophoretically at the skin reach the level of nociceptive axon terminals. 40 out of 48 patients suffering from chronic intractable pain of diverse etiology (postherpetic, paresthetic, ischaemic and trigeminal neuralgia, alcoholic and diabetic polyneuropathy, meralgia, brachialgia, discopathia, arthropathia and terminal pain) were successfully treated with Vinblastin or Vincristin iontophoresis. Iontophoretically applied microtubule inhibitors do not affect the blood cell count, have no side-effects and do not impair the skin at the site of application.
在大鼠中，微管抑制剂（长春碱、长春新碱、甲酰基-长春罗新）的经皮离子导入可导致原发性伤害性神经元中枢终末的耐氟酸性磷酸酶（FRAP）耗竭和跨神经节变性萎缩（trggl. deg. atr.），这可能是通过阻断外周感觉神经中的轴浆运输实现的。放射化学实验证明，经皮离子导入的微管抑制剂中约0.2%会到达伤害性轴突终末水平。48例患有各种病因（带状疱疹后、感觉异常、缺血性和三叉神经痛、酒精性和糖尿病性多发性神经病、股痛、臂痛、椎间盘病、关节病和末梢疼痛）的慢性顽固性疼痛患者中，有40例通过长春碱或长春新碱离子导入得到成功治疗。经皮离子导入的微管抑制剂不影响血细胞计数，无副作用，且不会损害应用部位的皮肤。
